Although RAS mutations alone do not confer a high risk of malignancy in thyroid nodules [18], their co-occurrence with other mutations, particularly within the TERT promoter, EIF1AX, or TP53 genes, significantly amplifies the risk of aggressive thyroid cancer [19]. The gene discussed is TP53; the disease is thyroid cancer.